Opthea Ltd OPT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 4:00 PM EDT
3.43quote price arrow up+0.16 (+4.89%)
Volume
13,083
52 week range
1.60 - 4.42
Loading...
  • Open3.31
  • Day High3.46
  • Day Low3.28
  • Prev Close3.27
  • 52 Week High4.42
  • 52 Week High Date05/01/23
  • 52 Week Low1.60
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap284.179M
  • Shares Out82.85M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change13.22

KEY STATS

  • Open3.31
  • Day High3.46
  • Day Low3.28
  • Prev Close3.27
  • 52 Week High4.42
  • 52 Week High Date05/01/23
  • 52 Week Low1.60
  • 52 Week Low Date10/27/23
  • Market Cap284.179M
  • Shares Out82.85M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta0.61
  • YTD % Change13.22

RATIOS/PROFITABILITY

  • EPS (TTM)-2.48
  • P/E (TTM)-1.38
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-165.133M
  • ROE (TTM)-3,383.08%
  • Revenue (TTM)117,100.00
  • Gross Margin (TTM)-99.74%
  • Net Margin (TTM)-138,008.09%
  • Debt To Equity (MRQ)-385.61%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Opthea Ltd

 

Profile

MORE
Opthea Limited is an Australia-based biotechnology company. The Company is engaged in the development and commercialization of therapies primarily for eye disease. The Company’s lead asset, OPT-302, is a novel biologic inhibitor of VEGF-C and VEGF-D, for use in combination with VEGF-A inhibitors for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The Company’s principal activities include the progression of the Company’s Phase...
Jeremy Levin Ph.D.
Non-Executive Independent Chairman of the Board
Frederic Guerard Pharm.D.
Chief Executive Officer
Peter Lang
Chief Financial Officer
Mark O'neill
Vice President - Chemistry, Manufacturing and Controls
John Han Pharm.D.
Vice President - Medical Affairs
Karen Adams CPA
Vice President - Finance, Company Secretary
Address
Suite 0403
Level 4, 650 Chapel Street, South Yarra
Melbourne, VIC
3141
Australia

Top Peers

SYMBOLLASTCHG%CHG
RAPT
RAPT Therapeutics Inc
7.70-0.18-2.28%
AVXL
Anavex Life Sciences Corp
3.65UNCHUNCH
VSTM
Verastem Inc
9.98+0.35+3.63%
VTYX
Ventyx Biosciences Inc
3.74-0.09-2.48%
LYRA
Lyra Therapeutics Inc
5.16+0.43+9.09%